About Cell Therapy
Cell therapy products, which are derived from stem cells, tissues, and organs grown in laboratories, are injected into patients. The growing number of clinical trials, government and private funding, and increasing number of partnerships between companies are driving the growth of the global cell therapy market. Cell therapy products that are available in the market are based on autologous and allogenic cells. The demand of cell therapy treatment is increasing. This is because cell therapy products can be used for personalized treatment.
Technavio’s analysts forecast the global cell therapy market to grow at a CAGR of 23.27% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global cell therapy market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Cell Therapy Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Dendreon
• Mesoblast
• Vericel
Other prominent vendors
• AlloCure
• Amorcyte
• Anterogen
• Antibe Therapeutics
• Astellas Pharma
• Athersys
• Avita Medical
• AxoGen
• Bellicum Pharmaceuticals
• BioCardia
• BIOCELLULAR THERAPIES
• Biogen Idec
• Bio-Tissue
• BIOTIME
• BioTissue Technologies
• BrainStorm Cell Therapeutics
• Bluebird Bio
• Bone Therapeutics
• Caladrius
• Capricor Therapeutics
• CellBioMed
• Celgene
• Cell Medica
• CellPraxis
• CellSeed
• Cell Therapy
• Celyad
• CESCA THERAPEUTICS
• CRC for Cell Therapy Manufacturing
• CryoLife
• Cynata Therapeutics
• Cytori Therapeutics
• DiscGenics
• Fate Therapeutics
• Fibrocell Science
• Forticell Bioscience
• Fortress Biotech
• Gamida Cell
• GlaxoSmithKline
• Healthpoint
• Histogen
• Histogenics
• Holostem Terapie Avanzate
• Humacyte
• Immunocellular Therapeutics
• Integra Life Sciences
• Intercytex
• iSTO Technologies
• Janssen Pharma
• Juno Therapeutics
• Juventas Therapeutics
• Kensey Nash
• Kite Pharma
• Kiadis Pharma
• LifeNet Health
• Living Cell Technologies
• Lonza
• MaxCyte
• MEDIPOST
• Nanofiber Solutions
• Nanotope
• Neuralstem
• Newlink Genetics
• Northwest Biotherapeutics
• NovaRx
• Ocata Therapeutics
• Opexa Therapeutics
• Orbsen Therapeutics
• Pfizer
• Pharmicell
• Pluristem Therapeutics
• Prima BioMed
• Q Therapeutics
• Regenerexx
• Regeneus
• Regenerys
• Regience
• Regrow
• RepliCel
• ReproCELL
• ReNeuron
• RenovaCare
• RESSTORE
• RhinoCyte
• Rohto Pharmaceutical
• SanBio
• Sangamo BioSciences
• Shanghai Sunway Biotech
• Shire Regenerative Medicine
• StemCells
• STEMPEUTICS RESEARCH
• Synergistic Technologies
• t2cure
• Takara Bio
• tella
• Tengion
• TissueGene
• Tessa Therapeutics
• Txcell
• VentriNova
• ViaCyte
• VistaGen Therapeutics
• SDRMI and Xcelthera
Market driver
• Increase in prevalence of chronic diseases
• For a full, detailed list, view our report
Market challenge
• High cost of clinical trials and cell therapy doses
• For a full, detailed list, view our report
Market trend
• Proliferation of strategic alliances and royalty payments
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Overview
• Government funding and support
PART 05: Market landscape
• Overview
• Market size and forecast
• PART 06: Pipeline portfolio
• Overview
• Regulatory framework for cell therapy products
• Pipeline analysis
• Five forces analysis
PART 07: Segmentation by application
• Overview
• Dermatology
• Musculoskeletal
• Ocular
• Cardiovascular
PART 08: Segmentation by end-user
• Hospitals and clinics
• ASCs
• Regenerative medicine centers
PART 09: Segmentation by geography
• Overview
• Americas
• EMEA
• APAC
PART 10: Decision framework
PART 11: Drivers and challenges
• Market drivers
• Market challenges
PART 12: Market trends
• Focus on business strategies
• Proliferation of strategic alliances and royalty payments
• Geographic expansion of gene therapy
PART 13: Vendor landscape
• Competitive landscape
• PART 14: Key vendor analysis
• Dendreon
• Mesoblast
• Vericel
• Other prominent vendors
PART 15: Appendix
• List of abbreviations
?
List of Exhibits
Exhibit 01: Types of stem cells used in cell therapy products: Overview
Exhibit 02: Collaborative funding for cell therapy-based research in US
Exhibit 03: Ethical challenges associated with stem cell research
Exhibit 04: Stem cell research policies in countries in Americas
Exhibit 05: Stem cell research policies in countries in EMEA
Exhibit 06: Stem cell research policies in countries in APAC
Exhibit 07: Global cell therapy market 2016-2021 ($ billions)
Exhibit 08: Global cell therapy market: Overview
Exhibit 09: Cell therapy pipeline for CVDs
Exhibit 10: Cell therapy pipelines for CNS, orthopedic, and ocular disorders
Exhibit 11: Cell therapy pipeline for dermatology and diabetes
Exhibit 12: Cell therapy pipeline for oncology
Exhibit 13: Five forces analysis
Exhibit 14: Global stem cell therapy market: Segmentation by application 2016 (% share)
Exhibit 15: Cell therapy for dermatology: Overview
Exhibit 16: Cell therapy for burns and diabetic wound treatment: Opportunity analysis
Exhibit 17: Cell therapy products for dermatology pipeline
Exhibit 18: Cell therapy for musculoskeletal: Overview
Exhibit 19: Cell therapy for occupational and sports-related injuries: Overview
Exhibit 20: Cell therapy for musculoskeletal pipeline
Exhibit 21: Cell therapy for ocular: Overview
Exhibit 22: Cell therapy for ocular pipeline
Exhibit 23: Cell therapy for cardiovascular: Overview
Exhibit 24: Cell therapy for cardiovascular: Overview
Exhibit 25: Global cell therapy market: Overview of segmentation by end-user
Exhibit 26: Funding and partnership for cell therapy product development
Exhibit 27: Hospital collaborations for cell therapy
Exhibit 28: Global cell therapy market: Segmentation by geography 2016 and 2021 ($ billions)
Exhibit 29: Cell therapy market in Americas: Overview
Exhibit 30: Cell therapy market in Americas 2016-2021 ($ billions)
Exhibit 31: Cell therapy market in Americas: Overview by country
Exhibit 32: SBIR and STTR programs
Exhibit 33: Cell therapy market in US: Overview
Exhibit 34: Cell therapy market in EMEA: Overview
Exhibit 35: Cell therapy market in EMEA 2016-2021 ($ billions)
Exhibit 36: Cell therapy market in EMEA: Overview by country
Exhibit 37: Cell therapy market in UK
Exhibit 38: Cell therapy market in APAC 2016-2021 ($ billions)
Exhibit 39: Cell therapy market in APAC: Overview by country
Exhibit 40: Cell therapy market in Japan: Overview
Exhibit 41: Chronic diseases in US and Europe
Exhibit 42: Fall and hip fracture in US 2016
Exhibit 43: Number of road injuries in UK 2015
Exhibit 44: Regulatory challenges associated with regenerative medicine
Exhibit 45: Key business strategies adopted by companies
Exhibit 46: Major strategic alliances
Exhibit 47: Competitive structure analysis
Exhibit 48: Competitive landscape
Exhibit 49: Strategies for companies
Exhibit 50: Key recommendations for new entrants
Exhibit 51: Dendreon: Key highlights
Exhibit 52: Dendreon: Strength assessment
Exhibit 53: Dendreon: Strategy assessment
Exhibit 54: Dendreon: Opportunity assessment
Exhibit 55: Mesoblast: Key highlights
Exhibit 56: Mesoblast: Strength assessment
Exhibit 57: Mesoblast: Strategy assessment
Exhibit 58: Mesoblast: Opportunity assessment
Exhibit 59: Vericel: Key highlights
Exhibit 60: Vericel: Strength assessment
Exhibit 61: Vericel: Strategy assessment
Exhibit 62: Vericel: Opportunity assessment
